{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:57:53Z","timestamp":1790258273967,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1C1A1A01051508"],"award-info":[{"award-number":["2015R1C1A1A01051508"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016RD1A1B03933826"],"award-info":[{"award-number":["2016RD1A1B03933826"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health and Welfare of the Republic of Korea","award":["1720140"],"award-info":[{"award-number":["1720140"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.canlet.2017.11.016","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T23:31:24Z","timestamp":1511393484000},"page":"205-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis"],"prefix":"10.1016","volume":"414","author":[{"given":"Changki","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Mi","family":"Whang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preston","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Mulcrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Elefteriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Wook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-5096","authenticated-orcid":false,"given":"Serk In","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2017.11.016_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/875305","article-title":"Dissecting the role of bone marrow stromal cells on bone metastases","volume":"2014","author":"Buenrostro","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.canlet.2017.11.016_bib2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.21778","article-title":"Metastatic patterns in adenocarcinoma","volume":"106","author":"Hess","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2017.11.016_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12307-011-0081-8","article-title":"Roles of bone marrow cells in skeletal metastases: no longer bystanders","volume":"4","author":"Park","year":"2011","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.canlet.2017.11.016_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11914-016-0315-2","article-title":"The bone microenvironment: a fertile soil for tumor growth","volume":"14","author":"Buenrostro","year":"2016","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.canlet.2017.11.016_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/fon.12.76","article-title":"The multifaceted actions of PTHrP in skeletal metastasis","volume":"8","author":"Soki","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2017.11.016_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3803\/EnM.2016.31.4.485","article-title":"Osteoblasts are the centerpiece of the metastatic bone microenvironment","volume":"31","author":"Jeong","year":"2016","journal-title":"Endocrinol. Metab. Seoul."},{"key":"10.1016\/j.canlet.2017.11.016_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.11005\/jbm.2014.21.1.8","article-title":"Bone biology and anabolic therapies for bone: current status and future prospects","volume":"21","author":"Martin","year":"2014","journal-title":"J.\u00a0Bone Metab."},{"key":"10.1016\/j.canlet.2017.11.016_bib8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI43414","article-title":"Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow","volume":"121","author":"Shiozawa","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.canlet.2017.11.016_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.11.016_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2014.02.013","article-title":"Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort","volume":"67","author":"Basch","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2017.11.016_bib11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jbmr.5650100203","article-title":"Development and characterization of a conditionally immortalized human fetal osteoblastic cell line","volume":"10","author":"Harris","year":"1995","journal-title":"J.\u00a0Bone Min. Res."},{"key":"10.1016\/j.canlet.2017.11.016_bib12","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/0008-5472.CAN-12-4692","article-title":"Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth","volume":"73","author":"Park","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.11.016_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbrc.2015.11.122","article-title":"Inhibition of cyclic AMP response element-directed transcription by decoy oligonucleotides enhances tumor-specific radiosensitivity","volume":"469","author":"Park","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2017.11.016_bib14","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.11.016_bib15","doi-asserted-by":"crossref","first-page":"53168","DOI":"10.18632\/oncotarget.18230","article-title":"MEK inhibition enhances efficacy of bacillus Calmette-Gu\u00e9rin on bladder cancer cells by reducing release of Toll-like receptor 2-activated antimicrobial peptides","volume":"8","author":"Whang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.11.016_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph1415s51","article-title":"Pre-clinical mouse models of human prostate cancer and their utility in drug discovery","author":"Park","year":"2010","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.canlet.2017.11.016_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001363","article-title":"Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice","volume":"10","author":"Campbell","year":"2012","journal-title":"PLoS Biol."},{"key":"10.1016\/j.canlet.2017.11.016_bib18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/ijc.28169","article-title":"Ligand-independent activation of MET through IGF-1\/IGF-1R signaling","volume":"133","author":"Varkaris","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2017.11.016_bib19","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1158\/0008-5472.CAN-12-3775","article-title":"EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis","volume":"73","author":"Breindel","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.11.016_bib20","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.11.016_bib21","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/13543784.2011.631523","article-title":"The role of HGF\/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials","volume":"20","author":"Varkaris","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2017.11.016_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.intimp.2012.03.026","article-title":"Hepatocyte growth factor-induced BMP-2 expression is mediated by c-Met receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts","volume":"13","author":"Tsai","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2017.11.016_bib23","article-title":"Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2017.11.016_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","article-title":"Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions","volume":"20","author":"Dai","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.11.016_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/1078-0432.CCR-13-2636","article-title":"Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?","volume":"20","author":"Lee","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.11.016_bib26","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-13-0459","article-title":"The novel VEGF receptor\/MET-targeted kinase inhibitor TAS-115 has marked in\u00a0vivo antitumor properties and a favorable tolerability profile","volume":"12","author":"Fujita","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.11.016_bib27","doi-asserted-by":"crossref","first-page":"20891","DOI":"10.1074\/jbc.M116.727875","article-title":"The MET\/vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor also attenuates FMS-dependent osteoclast differentiation and bone destruction induced by prostate cancer","volume":"291","author":"Watanabe","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.11.016_bib28","doi-asserted-by":"crossref","first-page":"20113","DOI":"10.18632\/oncotarget.15390","article-title":"Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions","volume":"8","author":"Fioramonti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.11.016_bib29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-16-0778","article-title":"Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity","volume":"7","author":"Patnaik","year":"2017","journal-title":"Cancer Discov."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517307383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517307383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T17:58:55Z","timestamp":1535219935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383517307383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":29,"alternative-id":["S0304383517307383"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2017.11.016","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2017.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}